Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2012 - 2025)

Ani Pharmaceuticals has disclosed Preferred Stock Liabilities across 6 years of filings, most recently posting $24.8 million for Q2 2025.

• In Q2 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $24.8 million; the TTM figure through Jun 2025 stood at $24.8 million (changed 0.0% YoY), while the FY2024 annual figure was $24.8 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities came in at $24.8 million for Q2 2025 at Ani Pharmaceuticals, roughly flat from $24.8 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $24.8 million in Q4 2021 to a low of $24.8 million in Q4 2021.
• Average Preferred Stock Liabilities over 5 years is $24.8 million, with a median of $24.8 million recorded in 2021.
• The largest YoY upside for Preferred Stock Liabilities was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
• Over 5 years, Preferred Stock Liabilities stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $24.8 million in Q2 2025, $24.8 million in Q1 2025, and $24.8 million in Q4 2024.